Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Genmab ( (GMAB) ).
Genmab A/S, the Copenhagen-headquartered biotech specializing in antibody-based cancer therapies and other serious disease treatments, has spent more than 25 years advancing next-generation modalities such as bispecific antibodies, antibody–drug conjugates and immune-modulating antibodies. Its science underpins eight approved antibody medicines and a late-stage clinical pipeline supported by operations across North America, Europe and Asia Pacific.
On March 30, 2026, Genmab disclosed that Orbis Investment Management Limited had become a major shareholder, holding voting rights for 3,205,763 Genmab shares as of March 27, 2026, equivalent to 4.99% of the company’s share capital and voting rights. The move marks a notable institutional stake in Genmab, signaling continued investor interest in the company’s antibody platform and late-stage pipeline and potentially strengthening its shareholder base as it advances its oncology and serious-disease portfolio.
The most recent analyst rating on (GMAB) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of antibody-based formats, including bispecifics, antibody–drug conjugates and immune-modulating antibodies, powering eight approved therapies and a strong late-stage pipeline.
Average Trading Volume: 1,792,288
Technical Sentiment Signal: Sell
Current Market Cap: $15.96B
For an in-depth examination of GMAB stock, go to TipRanks’ Overview page.